Evidence map›Paper›PMID 38849861›Full record

ArticleIMA fungus2024

Phylogenomic approaches reveal a robust time-scale phylogeny of the Terminal Fusarium Clade.

Andrés Felipe Lizcano Salas, Jorge Duitama, Silvia Restrepo, Adriana Marcela Celis Ramírez

Abstract read
In one paragraph

Article in IMA fungus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrés Felipe Lizcano SalasGrupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMop), Universidad de los Andes, Bogotá, Colombia.
Jorge DuitamaSystems and Computing Engineering Department, Universidad de los Andes, Bogotá, Colombia.
Silvia RestrepoChemical Engineering Department, Universidad de los Andes, Bogotá, Colombia.
Adriana Marcela Celis RamírezGrupo de Investigación Celular y Molecular de Microorganismos Patógenos (CeMop), Universidad de los Andes, Bogotá, Colombia. acelis@uniandes.edu.co.ORCID http://orcid.org/0000-0003-3057-1966

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Terminal Fusarium Clade (TFC) is a group in the Nectriaceae family with agricultural and clinical relevance. In recent years, various phylogenies have been presented in the literature, showing disagreement in the topologies, but only a few studies have conducted analyses on the divergence time scale of the group. Therefore, the evolutionary history of this group is still being determined. This study aimed to understand the evolutionary history of the TFC from a phylogenomic perspective. To achieve this objective, we performed a phylogenomic analysis using the available genomes in GenBank and ran eight different pipelines. We presented a new robust topology of the TFC that differs at some nodes from previous studies. These new relationships allowed us to formulate new hypotheses about the evolutionary history of the TFC. We also inferred new divergence time estimates, which differ from those of previous studies due to topology discordances and taxon sampling. The results suggested an important diversification process in the Neogene period, likely associated with the diversification and predominance of terrestrial ecosystems by angiosperms. In conclusion, we presented a robust time-scale phylogeny that allowed us to formulate new hypotheses regarding the evolutionary history of the TFC.

Indexed as

BisifusariumDiversification timeEvolutionNeocosmosporaNeogeneOrthologsRectifusarium

Identifiers

PMID38849861
PMCPMC11161934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.